Turk Ilac ve Serum Sanayi AS

Turk Ilac ve Serum Sanayi AS exhibits a capital structure with a debt-to-equity ratio of 1.57, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.04 and negative cash and equivalents of -65,640 TRY. This suggests limited short-term liquidity to cover immediate obligations. Profitability metrics show a challenging performance, with a return on equity of -38.38% and a return on assets of -9.04%. These figures are below the typical expectations for the pharmaceutical industry, which generally sees positive returns due to high-margin product offerings. The company's net income is negative at -622,649,700 TRY, indicating a significant loss in the latest reporting period. The company's revenue is concentrated in its domestic operations, with no disclosed international revenue segments. As a representative for other pharmaceutical companies, Turk Ilac's exposure to domestic market conditions is high, which could limit its ability to diversify risk through geographic expansion. Growth trajectory appears to be under pressure, with a net loss in the latest period and a negative free cash flow of -817,909,580 TRY. The company's operating cash flow of 613,903,480 TRY provides some buffer, but the negative free cash flow suggests that capital expenditures are outpacing operating cash inflows. This could hinder the company's ability to invest in growth initiatives. Risk factors include a negative net cash position after subtracting total debt, which raises concerns about liquidity and financial flexibility. The company's dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted measures. However, the negative net income and high debt levels could pressure the company to seek additional financing, potentially leading to future dilution. Recent events include a significant net loss and negative free cash flow, which may signal operational challenges. The company's capital expenditures of -256,109,370 TRY indicate ongoing investment in infrastructure, but the negative free cash flow suggests that these investments are not yet generating sufficient returns to cover costs.